EXEL — Exelixis Inc. stock price and chart

EXEL

Exelixis Inc.Stock · Health CareNasdaq Composite 0.03% · Russell 1000 0.02% · Russell 3000 0.02% · US Stock Market 0.02%

$58.33-0.27%

as of market close, Sep 18, 2026

☾ AH — —

PeersMRNALLYUNHJNJMRKTMO

Technical analysis2

Overlay lines0

Addendum charts0

Volume

20162019202120242026

10.015.020.025.030.035.040.045.050.055.0050.0M$58.36

2026-09-18

Price$58.36

MA20$52.40

MA50$45.82

Vol10.9M

What would $1,000 invested in EXEL be worth today? →

EXEL returns: By year · By month · By week · Trailing

Key stats

Price data

Price: $58.36
Change YTD: +33.15%
Next earnings: Nov 3, 2026
Market cap: 14.5B2016-09 3.7B2026-09 14.5B+294.7% over the window
Enterprise value: 13.8B
Shares outstanding: 247.8M2016-06 230.3M2026-07 247.8M+7.6% over the window
52W low: $33.76
52W high: $59.72
From 52W high: -2.28%
From 52W low: +72.87%
52W range: 95%
Beta: 0.41

Volume

Rel volume: 2.30×
30D volume: 2.3M
30D $ vol: 126.1M

Fundamentals

Sales (ttm): 2.4B2016-06 71.5M2026-07 2.4B+3308.3% over the window
Sales/share: $9.832016-06 $0.312026-07 $9.83+3068.2% over the window
EPS (ttm): $3.182016-06 -$0.792026-07 $3.18-502.7% over the window
FCF (ttm): 1.2B2016-06 60.5M2026-07 1.2B+1837.7% over the window
FCF/share: $4.732016-06 $0.262026-07 $4.73+1701.2% over the window
Book value/share: $7.442016-06 -$0.812026-07 $7.44-1020.8% over the window
Net margin: 35.33%2016-06 -253.5%2026-07 35.3%-113.9% over the window
ROE: 46.68%2016-09 -458.8%2026-07 46.7%-110.2% over the window
ROA: 34.50%2016-06 -38.0%2026-07 34.5%-190.9% over the window
Current ratio: 3.462016-06 1.832026-07 3.46+88.5% over the window

Growth (CAGR, ttm) · 10Y

Sales: +9.27%2025-07-04 → 2026-07-032.2B → 2.4B (+9.2% total)+12.39%2023-06-30 → 2026-07-031.7B → 2.4B (+42.1% total)+16.06%2021-07-02 → 2026-07-031.2B → 2.4B (+110.6% total)+42.28%2016-06-30 → 2026-07-0371.5M → 2.4B (+3308.3% total)
Net income: +43.07%2025-07-04 → 2026-07-03602.3M → 860.6M (+42.9% total)+73.41%2023-06-30 → 2026-07-03164.2M → 860.6M (+424.0% total)+55.68%2021-07-02 → 2026-07-0394M → 860.6M (+815.2% total)n/a
FCF: +55.72%2025-07-04 → 2026-07-03754.1M → 1.2B (+55.5% total)+48.55%2023-06-30 → 2026-07-03356.4M → 1.2B (+228.9% total)+39.97%2021-07-02 → 2026-07-03218.1M → 1.2B (+437.6% total)+34.47%2016-06-30 → 2026-07-0360.5M → 1.2B (+1837.7% total)
Shares: -7.98%2025-07-04 → 2026-07-03269.2M → 247.8M (-8.0% total)-7.99%2023-06-30 → 2026-07-03318.4M → 247.8M (-22.2% total)-4.69%2021-07-02 → 2026-07-03315M → 247.8M (-21.4% total)+0.73%2016-06-30 → 2026-07-03230.3M → 247.8M (+7.6% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: +53.11%2025-07-04 → 2026-07-03$2.08 → $3.18 (+52.9% total)+84.49%2023-06-30 → 2026-07-03$0.50 → $3.18 (+531.4% total)+60.82%2021-07-02 → 2026-07-03$0.30 → $3.18 (+976.7% total)n/a
Sales/share: +18.75%2025-07-04 → 2026-07-03$8.28 → $9.83 (+18.7% total)+22.15%2023-06-30 → 2026-07-03$5.38 → $9.83 (+82.6% total)+21.77%2021-07-02 → 2026-07-03$3.67 → $9.83 (+167.8% total)+41.25%2016-06-30 → 2026-07-03$0.31 → $9.83 (+3068.2% total)
FCF/share: +69.23%2025-07-04 → 2026-07-03$2.80 → $4.73 (+68.9% total)+61.45%2023-06-30 → 2026-07-03$1.12 → $4.73 (+322.7% total)+46.85%2021-07-02 → 2026-07-03$0.69 → $4.73 (+583.6% total)+33.50%2016-06-30 → 2026-07-03$0.26 → $4.73 (+1701.2% total)
Book value/share: -1.50%2025-07-04 → 2026-07-03$7.55 → $7.44 (-1.5% total)-2.13%2023-06-30 → 2026-07-03$7.94 → $7.44 (-6.3% total)+2.79%2021-07-02 → 2026-07-03$6.48 → $7.44 (+14.7% total)n/a
Price: +44.31%2025-09-18 → 2026-09-18$40.45 → $58.36 (+44.3% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+39.81%2023-09-18 → 2026-09-18$21.35 → $58.36 (+173.3% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+23.00%2021-09-17 → 2026-09-18$20.72 → $58.36 (+181.7% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+15.72%2016-09-16 → 2026-09-18$13.55 → $58.36 (+330.7% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +44.31%2025-09-18 → 2026-09-18$40.45 → $58.36 (+44.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+39.81%2023-09-18 → 2026-09-18$21.35 → $58.36 (+173.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+23.00%2021-09-17 → 2026-09-18$20.72 → $58.36 (+181.7% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+15.72%2016-09-16 → 2026-09-18$13.55 → $58.36 (+330.7% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 18.3×2016-09 -24.942026-09 16.80-167.4% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 14.9×2016-09 -37.162026-09 14.88-140.1% over the window
Fwd P/E: 13.3×
P/S (ttm)Market cap ÷ TTM revenue.: 5.9×2016-09 29.592026-09 5.94-79.9% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 7.8×2016-09 114.412026-09 7.84-93.1% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 12.3×2016-09 41.192026-09 12.33-70.1% over the window
EV/EBITDA (fy): 13.8×
EV/Sales (ttm): 5.7×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 8.11%2016-06 1.7%2026-07 8.6%+419.1% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-07-03) ÷ shares_at(2025-07-04) = 1 − 247.8M ÷ 269.2M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: 7.98%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (7.98%) + dividends paid over that year ($0) ÷ market_cap_at(2025-07-04) ($12.6B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: 7.98%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($1.1B) ÷ today's market cap ($14.5B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 7.71%2016-06 -4.0%2026-07 8.2%-305.1% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $1.1B + TTM dividends $0) ÷ today's market cap ($14.5B). Same caveat as the cash buyback yield.: 7.71%2016-06 -4.0%2026-07 8.2%-305.1% over the window

Vs own 10Y history

P/E: 27th
P/OI: 24th
P/S: 57th
P/B: 81st
P/FCF: 12th

Bar = where today’s multiple sits in EXEL’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-09-18

-0.27%

+3.99%

+9.86%

+12.43%

YTD

+33.15%

+44.28%

+181.66%

Financial statements

Open full EXEL financials →

Loading financial statements…

Ticker	Name	1M	1D
NVS	Novartis AG	-9.18%	-0.38%
NVO	Novo Nordisk A/S	-5.40%	+0.12%
SNY	Sanofi ADS	-7.11%	+0.26%
GSK	GSK plc American Depositary Shares (Each representing two Ordinary Shares)	-1.82%	-1.66%
ARGX	argenx SE American Depositary Shares	-4.83%	-0.07%
TAK	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	+4.76%	-0.71%
NTRA	Natera Inc.	+18.51%	+0.84%
TEVA	Teva Pharmaceutical Industries Limited American Depositary Shares	+6.56%	-0.48%

Exelixis Inc. (EXEL) trades at $58.33 with a live price and an interactive chart covering 26+ years of daily price history, plus key valuation metrics. ChartRow also publishes EXEL’s financial statements free — annual and quarterly income statement, balance sheet, and cash flow straight from SEC filings, with P/E and valuation history and dividend data. See full EXEL financial statements →

EXEL — Exelixis Inc. price, chart and key statistics

Key stats

Price data

Volume

Fundamentals

Growth (CAGR, ttm) · 10Y

Per-share growth (CAGR, ttm) · 10Y

Valuation

Vs own 10Y history

Performance · price return · as of 2026-09-18

Financial statements

Related Health Care